Abstract | Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized by the degeneration of both upper and lower motor neurons, which leads to muscle weakness and eventual paralysis. Until recently, ALS was classified primarily within the neuromuscular domain, although new imaging and neuropathological data have indicated the involvement of the non-motor neuraxis in disease pathology. In most patients, the mechanisms underlying the development of ALS are poorly understood, although a subset of patients have familial disease and harbour mutations in genes that have various roles in neuronal function. Two possible disease-modifying therapies that can slow disease progression are available for ALS, but patient management is largely mediated by symptomatic therapies, such as the use of muscle relaxants for spasticity and speech therapy for dysarthria

Amyotrophic lateral sclerosis

Chio, Adriano;
2017-01-01

Abstract

Abstract | Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized by the degeneration of both upper and lower motor neurons, which leads to muscle weakness and eventual paralysis. Until recently, ALS was classified primarily within the neuromuscular domain, although new imaging and neuropathological data have indicated the involvement of the non-motor neuraxis in disease pathology. In most patients, the mechanisms underlying the development of ALS are poorly understood, although a subset of patients have familial disease and harbour mutations in genes that have various roles in neuronal function. Two possible disease-modifying therapies that can slow disease progression are available for ALS, but patient management is largely mediated by symptomatic therapies, such as the use of muscle relaxants for spasticity and speech therapy for dysarthria
2017
3
17071
17088
http://www.nature.com/nrdp/
Humans; Amyotrophic Lateral Sclerosis; Medicine (all)
Hardiman, Orla*; Al-Chalabi, Ammar; Chio, Adriano; Corr, Emma M.; Logroscino, Giancarlo; Robberecht, Wim; Shaw, Pamela J.; Simmons, Zachary; Van Den Berg, Leonard H.
File in questo prodotto:
File Dimensione Formato  
NRN Primer Draft 2 March 20 2017.docx

Accesso riservato

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 278.95 kB
Formato Microsoft Word XML
278.95 kB Microsoft Word XML   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1673179
Citazioni
  • ???jsp.display-item.citation.pmc??? 472
  • Scopus 961
  • ???jsp.display-item.citation.isi??? 597
social impact